Lipella PharmaceuticalsLIPO
About: Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Employees: 7
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
7.22% less ownership
Funds ownership: 8.28% [Q2] → 1.06% (-7.22%) [Q3]
29% less funds holding
Funds holding: 7 [Q2] → 5 (-2) [Q3]
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
86% less capital invested
Capital invested by funds: $284K [Q2] → $39.7K (-$244K) [Q3]
100% less funds holding in top 10
Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]
Research analyst outlook
We haven’t received any recent analyst ratings for LIPO.
Financial journalist opinion
Based on 6 articles about LIPO published over the past 30 days
